Literature DB >> 33321079

Are Nursing Home Residents With Dementia Appropriately Treated for Fracture Prevention?

Joshua D Niznik1, Xintong Li2, Meredith A Gilliam3, Laura C Hanson3, Sherrie L Aspinall4, Cathleen Colon-Emeric5, Carolyn T Thorpe6.   

Abstract

Clinicians struggle with whether to prescribe osteoporosis medications for fracture prevention for older nursing home (NH) residents with dementia, given the lack of evidence in this population. To better understand real-world clinical practice, we conducted a retrospective cohort study examining patterns of fracture prevention medication use for older NH residents with dementia and high fracture risk. Data sources included 2015-16 Medicare claims, Part D prescriptions, and Minimum Data Set (MDS) assessments. Among NH residents aged 65+ with dementia and prior fracture or high fracture risk based on the MDS FRAiL (Fracture Risk Assessment in Long-term care), we assessed medications for fracture prevention using prescription data from 1 year prior through 90 days after the first MDS assessment. Multivariable logistic regression was used to evaluate factors associated with receiving treatment. Most of the sample (n = 72,639) was >80 years (78%), female (82%), and white (88%); 63% had moderate/severe dementia and 60% had an osteoporosis diagnosis. Only 11.6% received fracture prevention medications. In adjusted analyses, treated residents were more likely to be female, Hispanic or other non-black minority, <90 years old, and newly admitted to the NH. Other associated factors included osteoporosis diagnosis, walker or wheelchair use, bone disorders (eg, Paget disease), >5 medications, steroid or proton pump inhibitor use, and regions outside of the Northeast. Resident characteristics suggestive of comorbidity burden and worsening dementia were associated with reduced likelihood of treatment. Low use of fracture prevention medications for NH residents with dementia may reflect an attempt by prescribers reconcile medication use with changing goals of care, or inappropriate underuse in patients who still have high fracture risk. Additional research is needed to help clinicians better evaluate when to use these medications in this heterogeneous and vulnerable population.
Copyright © 2020 AMDA – The Society for Post-Acute and Long-Term Care Medicine. All rights reserved.

Entities:  

Keywords:  Dementia; Medicare; fractures; medications; osteoporosis

Mesh:

Year:  2020        PMID: 33321079      PMCID: PMC8358966          DOI: 10.1016/j.jamda.2020.11.019

Source DB:  PubMed          Journal:  J Am Med Dir Assoc        ISSN: 1525-8610            Impact factor:   7.802


  36 in total

1.  Use of osteoporosis medications in older nursing facility residents.

Authors:  Rollin M Wright
Journal:  J Am Med Dir Assoc       Date:  2007-08-13       Impact factor: 4.669

2.  Osteoporosis Diagnosis and Management in Long-Term Care Facility.

Authors:  Erwin A Aguilar; Sean D Barry; Charles A Cefalu; Abir Abdo; William P Hudson; James S Campbell; Thomas M Reske; Machaon Bonafede; Kathleen Wilson; Bradley S Stolshek; Carly J Paoli; Nguyet Tran; Lung-I Cheng
Journal:  Am J Med Sci       Date:  2015-11       Impact factor: 2.378

3.  AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE.

Authors:  Pauline M Camacho; Steven M Petak; Neil Binkley; Dima L Diab; Leslie S Eldeiry; Azeez Farooki; Steven T Harris; Daniel L Hurley; Jennifer Kelly; E Michael Lewiecki; Rachel Pessah-Pollack; Michael McClung; Sunil J Wimalawansa; Nelson B Watts
Journal:  Endocr Pract       Date:  2020-05       Impact factor: 3.443

4.  Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.

Authors:  K N Hayes; J K Ban; G Athanasiadis; A M Burden; S M Cadarette
Journal:  Osteoporos Int       Date:  2019-07-17       Impact factor: 4.507

5.  Prevalence and predictors of osteoporosis treatment in nursing home residents with known osteoporosis or recent fracture.

Authors:  C Colón-Emeric; K W Lyles; D A Levine; P House; A Schenck; J Gorospe; M Fermazin; K Oliver; J Alison; N Weisman; A Xie; J R Curtis; K Saag
Journal:  Osteoporos Int       Date:  2006-11-21       Impact factor: 4.507

6.  Osteoporosis management among residents living in long-term care.

Authors:  L M Giangregorio; M Jantzi; A Papaioannou; J Hirdes; C J Maxwell; J W Poss
Journal:  Osteoporos Int       Date:  2009-02-10       Impact factor: 4.507

7.  Anti-osteoporotic therapy in Denmark--predictors and demographics of poor refill compliance and poor persistence.

Authors:  C Hansen; B D Pedersen; H Konradsen; B Abrahamsen
Journal:  Osteoporos Int       Date:  2012-11-22       Impact factor: 4.507

8.  Anti-osteoporosis drug prescribing after hip fracture in the UK: 2000-2010.

Authors:  C Klop; D Gibson-Smith; P J M Elders; P M J Welsing; H G M Leufkens; N C Harvey; J W J Bijlsma; T-P van Staa; F de Vries
Journal:  Osteoporos Int       Date:  2015-05-12       Impact factor: 4.507

9.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

10.  Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.

Authors:  A Keshishian; N Boytsov; R Burge; K Krohn; L Lombard; X Zhang; L Xie; O Baser
Journal:  Osteoporos Int       Date:  2017-05-23       Impact factor: 4.507

View more
  1 in total

1.  Improving shared decision-making for osteoporosis pharmacologic therapy in nursing homes: a qualitative analysis.

Authors:  Cathleen S Colón-Emeric; Emily J Hecker; Eleanor McConnell; Laurie Herndon; Milta Little; Tingzhong Xue; Sarah Berry
Journal:  Arch Osteoporos       Date:  2022-01-03       Impact factor: 2.879

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.